Clinical Trials Sponsored by Cereve, Inc.

Total 35597 results

Cereve, Inc.

Completed

Comparison of Two Temperatures to Treat Insomnia

Primary Insomnia

United States
Cereve, Inc.

Completed

30 Days in Home Use and Home Use Patterns Over 6 Months

Primary Insomnia

United States
Serene Medical Inc

Completed

Efficacy Trial for the Reduction of Glabellar Lines

Rhytids in the Glabellar Region

United States
Cervel Neurotech, Inc.

Completed

Treatment of Fibromyalgia Using Deep Shaped-Field Transcranial Magnetic Stimulation a Clinical Feasibility Study

Fibromyalgia

United States
Cervel Neurotech, Inc.

Completed

Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression

Major Depressive Disorder

United States, Australia
Cervel Neurotech, Inc.

Completed

A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)

Depressive Disorder, Major

United States
CereVu Medical, Inc.
John Muir Health

Recruiting

Breathing With a Facemask Exercise Performance

Pulmonary Disease, Chronic Obstructive

United States
Verve Therapeutics, Inc.

Not yet recruiting

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Heterozygous Familial Hypercholesterolemia

New Zealand, United Kingdom
Verve Therapeutics, Inc.

Active, not recruiting

A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Heterozygous Familial Hypercholesterolemia

New Zealand, United Kingdom
Verve Therapeutics, Inc.

Not yet recruiting

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Heterozygous Familial Hypercholesterolemia | Premature Coronary Heart Disease
Cerevel Therapeutics, LLC

Recruiting

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Panic Disorder

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Puerto Rico
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Cerevel Therapeutics, LLC

Completed

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

Parkinson Disease

Germany, Spain, United States, Australia, Bulgaria, Czechia, France, Israel, Italy, Poland, Ukraine, Serbia
Cerevel Therapeutics, LLC

Completed

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Enrolling by invitation

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Spain, Australia, Poland, Ukraine
Cerevel Therapeutics, LLC

Completed

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

Parkinson Disease

United States
Cerevel Therapeutics, LLC

Completed

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Schizophrenia

Belgium, United States
Cerevel Therapeutics, LLC

Completed

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Parkinson Disease

United States
Cerevel Therapeutics, LLC

Completed

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

Major Depressive Disorder

United States
Cerevel Therapeutics, LLC

Completed

A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects

Panic Disorder

Netherlands
Cerevel Therapeutics, LLC

Terminated

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Substance Use Disorders (SUD)

United States
Aarhus University Hospital
Ceremed, Inc.

Unknown

Improvement of Hemostasis Techniques After Median Sternotomy

Sternal Dehiscence | Sternal Infection | Sternal Pain

Denmark
Cerevel Therapeutics, LLC

Not yet recruiting

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Healthy Participants
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Recruiting

A Multiple Ascending Dose Trial of Emraclidine in Elderly Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Poland, Spain, Serbia, Australia, Ukraine
Cerevel Therapeutics, LLC

Enrolling by invitation

Open-label Trial in Parkinson's Disease (PD) (TEMPO-4)

Parkinson Disease

Poland, United States, Spain, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Serbia, Ukraine
Cerevel Therapeutics, LLC

Active, not recruiting

Flexible-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-2)

Parkinson Disease

Poland, Spain, United States, France, Germany, Hungary, Italy, Serbia, Ukraine, Australia, Korea, Republic of, Taiwan, Thailand
Cerevel Therapeutics, LLC

Completed

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

Healthy

United States
Cerevel Therapeutics, LLC

Completed

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Cerevel Therapeutics, LLC

Recruiting

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Opioid Use Disorder

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Apathy in Dementia

United States, Canada
Cerevel Therapeutics, LLC

Completed

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Healthy Volunteers

United States
Cerevel Therapeutics, LLC

Active, not recruiting

Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)

Parkinson Disease

Spain, United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Israel, Italy, Poland, Ukraine
Cerevel Therapeutics, LLC

Completed

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Active, not recruiting

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Healthy

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Schizophrenia | Blood Pressure

United States
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Cerevel Therapeutics, LLC

Completed

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

Schizophrenia

United States
Cerevel Therapeutics, LLC

Completed

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

Healthy Subjects

United States
Merete Haedersdal
Sebacia, Inc.

Completed

Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery

Acne Vulgaris | Microparticles

Denmark
Merete Haedersdal
Sebacia, Inc.

Completed

Imaging of Pilosebaceous Units and Acne Lesions by RCM and OCT Confocal Microscopy and Optical Coherence Tomography

Acne Vulgaris

Denmark
University of Miami
CeraVe

Completed

CeraVe Diabetes Mellitus

Diabetes Complications

United States
Cereneo AG

Terminated

Investigating Adherence to Cereneo Tele-service Support After Clinical Disharge in Stroke Patients

Stroke, Ischemic

Switzerland

3

Subscribe